What top creators are saying about Nektar Therapeutics(NKTR)

The speaker was down about 50% but continued holding the position. He said he did not know the company well and did not think buying more was a good idea.

The stock was described as continuing to drop, with its portfolio weight falling from 30% to 15%. The speaker was tempted to buy more but cautioned against adding because he did not know the company well.

The speaker described a holding that had fallen about 50% and said he did not know the company well and did not think one should buy more.

A speaker was strongly bearish, criticizing the company's interleukin-2 treatment approach and doubting its prospects for alopecia areata.

The speaker said the company's data did not look good or satisfy the market and stated that he had shorted the stock.

The speaker said Nektar's reported data did not please the market and that they generally had not liked the company.

The speaker said he did not know enough about the company to trade it.

The speaker was strongly bearish, criticizing the interleukin-2 treatment approach as potentially toxic and facing competition, though no clinical data or formal safety analysis was presented.

The host said they did not know enough about the company to trade it.

The speaker is long the stock but only in a 'very small amount,' indicating it's a speculative position with mild bullish conviction.

Mentioned as a neutral example of a company with a poor management track record that recently had a positive outcome, serving as a potential parallel for INMB's situation.

Viewed as a high-risk, high-reward speculation trading below its cash value. The speaker notes the asymmetric risk/reward (potential 10x return vs. 30% decline) makes it a tempting short-term trade ahead of data results, despite a history of failures.